# A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

> **NCT04456816** · PHASE2 · RECRUITING · sponsor: **SynAct Pharma Aps** · enrollment: 23 (estimated)

## Conditions studied

- Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
- Severe Proteinuria Due to Idiopathic Membranous Nephropathy

## Interventions

- **DRUG:** 100 mg AP1189
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04456816
- **Lead sponsor:** SynAct Pharma Aps
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-08-31
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 23 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04456816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04456816, "A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04456816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*